Homepage
No report run on this ticker yet
Only preliminary foundational data below
Sign in to run a fresh report
Free · results in ~10 min
For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Biotech Acquisition Company (BIOT) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Consumer Defensive · Household & Personal Products
Shinagawa, NY 141-0031, Japan
instinct-bro.com/en/businessdomain/instinctbrothers
Price
$0.56
Market Cap
$16.1M
Employees
0
Beta
—
Avg Volume
203,013
CEO
Mr. Tomoki Nagano
Instinct Brothers Co., Ltd. operates as a stem cell technology and regenerative medicine company. It also engages in the import, sales, management, and delivery of stem cell cosmetics. The company also provides stem cell beauty essence products. Instinct Brothers Co., Ltd. The company was incorporated in 2015 and is based in Shinagawa, Japan.
Runs with full report
Recent SEC Filings
Last updated: Jul 30, 2026 7:26am (1h ago)| Filed | Form | Document |
|---|---|---|
| Jul 29, 2026 | 20-F | View |
| Jul 28, 2026 | 6-K | View |
| Jul 23, 2026 | CERT | View |
| Jul 23, 2026 | 8-A12B | View |
| Mar 5, 2026 | 424B3 | View |
| Dec 3, 2025 | EFFECT | View |
| Nov 25, 2025 | POS AM | View |
| Oct 24, 2025 | F-4/A | View |
| Sep 26, 2025 | F-4/A | View |
| Sep 9, 2025 | F-4 | View |
| Aug 12, 2025 | DRS/A | View |
| Jun 23, 2025 | DRS/A | View |
Filings link to the SEC’s EDGAR system. Annual/quarterly reports (10-K, 10-Q, 20-F) carry the full story; 8-K/6-K current reports are the fastest signal that something material happened.
Price Overview
Last updated: Jul 30, 2026 9:14am (just now)
Current data · timestamped when a report runs
$0.56
Change · Jul 30
-0.77 (-57.89%)
Day Range
$0.41 – $0.83
52-Week Range
$0.41 – $50.00
50-Day MA
$9.72
200-Day MA
$9.83
Volume
5,741,377.00
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
TD Twelve Data statement
HEX SEC filing
P/E Ratio (Price per dollar of earnings)
HEXStock Price / EPS (Diluted)
-2.20
Stock Price: $0.56
EPS (Diluted): -0.25
EPS (Diluted): -0.25
P/B Ratio (Price vs net asset value)
HEXStock Price / Book Value Per Share
0.07
Stock Price: $0.56
Total Equity: $202.85M
Shares: 26,928,057
Total Equity: $202.85M
Shares: 26,928,057
EV/EBITDA (Total value vs operating profit)
HEXEnterprise Value / EBITDA
4.28
Market Cap: $16.14M
Total Debt: $0.00
Cash: $91,407
EBITDA: $3.75M
Total Debt: $0.00
Cash: $91,407
EBITDA: $3.75M
Enterprise Value (Takeover price (cap + debt - cash))
HEXMarket Cap + Total Debt - Cash
$16.0M
Market Cap: $16.14M
Total Debt: $0.00
Cash: $91,407
Total Debt: $0.00
Cash: $91,407
Gross Margin (Revenue left after direct costs)
HEXGross Profit / Revenue
—
Gross Profit: N/A
Revenue: $0.00
Revenue: $0.00
Missing from API: Gross Profit
Operating Margin (Revenue left after all operations)
HEXOperating Income / Revenue
—
Operating Income: -$1.57M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
HEXNet Income / Revenue
—
Net Income: -$6.86M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
HEXNet Income / Total Equity
-3.4%
Net Income: -$6.86M
Total Equity: $202.85M
Total Equity: $202.85M
ROIC (Profit from all invested capital)
HEXNOPAT / Invested Capital
-0.6%
Operating Income: -$1.57M
Tax Rate: N/A
Equity: $202.85M
Total Debt: $0.00
Cash: $91,407
Tax Rate: N/A
Equity: $202.85M
Total Debt: $0.00
Cash: $91,407
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
HEXCurrent Assets / Current Liabilities
—
Current Assets: $299,463
Current Liabilities: N/A
Current Liabilities: N/A
Missing from API: Current Liabilities
Debt/Equity (Leverage — debt vs equity)
HEXTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $202.85M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $202.85M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
HEXRevenue / Shares Outstanding
—
Revenue: $0.00
Shares: 26,928,057
Shares: 26,928,057
Book Value/Share (Net assets per share)
HEX(Total Assets - Total Liabilities) / Shares
$7.53
Total Equity: $202.85M
Shares: 26,928,057
Shares: 26,928,057
FCF/Share (Real cash generated per share)
HEX(Operating Cash Flow + CapEx) / Shares
$-0.24
Operating CF: -$6.37M
CapEx: $0.00
Shares: 26,928,057
CapEx: $0.00
Shares: 26,928,057
Div Yield (Annual income from holding)
TDLast Annual Dividend / Stock Price
—
Last Dividend: $0.00
Stock Price: $0.56
Stock Price: $0.56
Payout Ratio (Earnings paid out as dividends)
HEXDividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$6.86M
Net Income: -$6.86M
Dividends paid not available in cash flow statement
Income Statement (Annual)
Last updated: Jul 30, 2026 7:26am (1h ago)| Metric | 2021 |
|---|---|
| Revenue | $0 |
| Cost of Revenue | — |
| Gross Profit | — |
| Operating Expenses | — |
| Operating Income | -$1.6M |
| Net Income | -$6.9M |
| EBITDA | $3.7M |
| EPS | $-0.25 |
| EPS (Diluted) | $-0.25 |
Balance Sheet (Annual)
Last updated: Jul 30, 2026 7:26am (1h ago)| Metric | 2020 | 2021 |
|---|---|---|
| Cash & Equivalents | — | $91,407 |
| Total Current Assets | — | $299,463 |
| Total Assets | $89,500 | $230.3M |
| Current Liabilities | $69,500 | — |
| Long-Term Debt | — | — |
| Total Liabilities | $69,500 | — |
| Total Equity | $-4,425 | $202.9M |
| Retained Earnings | $-5,000 | -$27.2M |
Cash Flow (Annual)
Last updated: Jul 30, 2026 7:26am (1h ago)| Metric | 2021 |
|---|---|
| Operating Cash Flow | -$6.4M |
| Capital Expenditure | — |
| Free Cash Flow | -$1.5M |
| Acquisitions (net) | — |
| Net Debt Issued / (Repaid) | $-139,000 |
| Dividends Paid | — |
| Stock Buybacks | — |
| Net Change in Cash | -$10.9M |
Industry Benchmarks
Compares BIOT against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Advanced Analysis Forensic deep-dive · three lenses
Character & Durability Scorecard
Ten long-horizon business-character traits the Quality / Value / Sentiment lenses don’t break out, scored 1–10.
No scorecard yet for BIOT — the ten traits are scored by the
pipeline (
ext-scorecard step) when a report is run on this ticker.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for BIOT — it's generated by the pipeline (
market-narrative step).
Delvantic AI Findings
No AI findings yet for BIOT — they're generated by the
pipeline (
ai-findings step) when a report is run on this ticker.
GPT Critique
No GPT critique yet for BIOT — it's generated by the
pipeline (
gpt-critique step) after the AI findings above, when a
report is run on this ticker.
No community reviews yet for BIOT.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · twelvedata
v1.1.496 · 31f2d85f · 2026-07-29 20:18:08